Neurovation Labs, Inc. announces novel and effective methods for diagnosing and treating PTSD
New York, NY, April 11, 2016- A new New York-based biotechnology company, Neurovation Labs, Inc., is developing an objective diagnostic for Post-traumatic Stress Disorder (PTSD) and an accompanying treatment. Early research has shown that a complete reversal of PTSD is possible.
Breakthrough research led to the discovery of a putative biomarker in the brain using a robust rodent model that mimics nearly all characteristics of PTSD. The biomarker provides a tangible physiological indicator of the mental disorder. In particular, Dr. Michael Fanselow, Director of R&D, and Dr. Jennifer Perusini, CEO, observed an enduring neural alteration—an increase in levels of a protein contained within the amygdala, a region of the brain responsible for fear—after the rodents experience a trauma (Perusini et al., 2015). This protein is GluA1, a subunit of the glutamatergic AMPA receptor, and is known to be important for learning and memory but previously not identified as crucial for PTSD. Significantly, targeting the GluA1 increases within the brain completely reversed PTSD symptoms with virtually no side-effects and no amnesia for the actual trauma.
Drs. Fanselow and Perusini have created Neurovation Labs, Inc. to further develop PTSD diagnostics and treatments in humans. The protein biomarker provides the potential for a major advancement in PTSD diagnosis over current detection methods, which only use symptom checklists. Moreover, this putative biomarker is also the basis for a potential treatment, since stabilizing levels of the biomarker protein in the amygdala of the brain led to reversal of PTSD in the rodent studies. Based in New York, NY and founded in 2016, Neurovation Labs is poised to expand upon the foundational research and work towards diagnostics and cures that could help millions of people.